五株登革病毒的分离鉴定及E基因序列分析

登革病毒作为一种重要的蚊媒传播病毒,威胁全球人类健康,及时甚至实时了解病毒的变异和流行病学规律,对科学防控登革热具有重要意义.因此,本研究利用广东省深圳市发现的登革热患者血清进行病毒分离、鉴定及囊膜蛋白E基因的扩增、测序及生物信息学分析病毒E基因进化特点.结果显示,应用Vero和C6/36细胞培养法从登革热病患血清中分离获得5株登革病毒,利用MEGA7软件对囊膜蛋白E的核苷酸和氨基酸序列进行分析显示,5株均属血清Ⅱ型登革病毒,其中输入性SZ926株和本地株SZ38株同源性为99.5％,均与泰国16681经典毒株关系密切,可能衍生于同一祖先;SZ868株和SZ871株为境外输入性病患分离株,两株病毒核苷酸同源性达到99.9％,说明两株病毒可能源于同一毒株;SZ29株与新几内亚的New Guinea C毒株同源性为99.8％,显示出进化保守、稳定传播的特点.基因型分析显示,SZ926和SZ38为基因型Ⅲ型,SZ868和SZ871为基因型Ⅳ型,SZ29为基因型Ⅰ型.本研究成功分离获得5株血清Ⅱ型登革病毒,分属于3个基因型,且不同基因型的E基因整体变异较低,而且我国存在多种基因型感染的潜在威胁,必须加强防范意识和研究力度.     

登革2型病毒E蛋白结构域Ⅲ的表达及多克隆抗体制备

登革病毒（Dengue virus,DENV）属于黄病毒科（Flaviviridae）,黄病毒属（Flavivirus）,为单股正链RNA病毒,有4个不同的血清型（DENV-1,2,3,4）,主要通过埃及伊蚊（Aedes aegypti）和白纹伊蚊（Aedes albopictus）传播,可引起登革热、登革出血热、登革休克综合征等多种疾病。     

登革2型病毒E蛋白结构域Ⅲ的表达及多克隆抗体制备

登革病毒(Dengue virus, DENV)属于黄病毒科(Flaviviridae),黄病毒属(Flavivirus),为单股正链RNA病毒,有4个不同的血清型(DENV- 1,2,3,4),主要通过埃及伊蚊(Aedes aegypti)和白纹伊蚊(Aedes albopictus)传播,可引起登革热、登革出血热、登革休克综合征等多种疾病 [1,2].     

浙江省登革热暴发疫情的病原学和分子生物学研究

2004年浙江省慈溪市发生了由输入病例引起的登革热暴发,共报告病例113例。为查明病因,从分子水平分析流行毒株的生物学特征,对疑似患者血清测定了登革病毒IgM和IgG抗体,并用C6/36和BHK-21细胞分离登革病毒。同时采用RT-PCR方法扩增病毒E基因和NS1基因后又分别进行序列测定,并与不同国家和地区的登革热毒株进行同源性和进化树分析。结果表明,从患者血清中检测到登革病毒IgM和IgG抗体及登革I型病毒核酸;从18份疑似患者血清中分离到10株登革I型病毒;浙江登革I型分离株(ZJ/07/04)与登革I型夏威夷株、广东株和泰国株的E基因氨基酸同源性分别为96.3%、98.8%和99.2%,而与登革Ⅱ、Ⅲ、Ⅳ型毒株相同区域氨基酸同源性分别为68.3%、77.5%和62.8%。基因进化树显示浙江省登革病毒分离株与泰国株亲缘关系最近,在进化树的同一分支上。从病原学、血清学和分子生物学特征上均证实该次疫情的病因为由泰国输入的登革I型病毒。     

登革2型病毒E蛋白结构域III的表达及多克隆抗体制备

登革病毒(Dengue virus,DENV)属于黄病毒科(Flaviviridae),黄病毒属(Flavivirus),为单股正链RNA病毒,有4个不同的血清型(DENV-1,2,3,4),主要通过埃及伊蚊(Aedes aegypti)和白纹伊蚊(Aedes albopictus)传播,可引起登革热、登革出血热、登革休克综合征等多种疾病[1,2]。E蛋白是位于DENV表面的结构蛋白,由495个氨基酸组成,它既含有黄病毒亚群特异的和登革病毒血清型特异的抗原表位,又有与中和,血凝抑制作用有关的抗原表位,是病毒颗粒的主要包膜蛋白[3]。Modis等研究表明,DENV-2型E蛋白以延伸的二聚体形式平铺在病毒表面,折叠成3个不…     

登革热的传播模式、蚊媒及防控

在自然界存在两种登革热传播模式:人-伊蚊-人循环,蚊媒是埃及伊蚊与白纹伊蚊。猴-伊蚊-猴循环,蚊媒是白纹伊蚊与白雪伊蚊群。我国学者首先于1975年从无输入性病例的我国西南边疆山林地区的白纹伊蚊体内分离到登革热病毒4型,白纹伊蚊承担两种传播模式的中介。本研究介绍了埃及伊蚊与白纹伊蚊的生态习性与全球及在中国的分布。认为在我国厦门地区迄今为止还未曾发现过埃及伊蚊的存在,也简介了沃尔巴克体新技术防控蚊媒研究的进展。     

本期重点推介

正登革病毒(dengue virus)是一种流行广泛的蚊媒病毒,主要经伊蚊Aedes传播,可导致登革热等重大疾病。由于长期使用杀虫剂对蚊媒进行防控,使蚊虫产生了抗药性。为了检验蚊虫抗药性对其感染和传播病毒的影响,南方医科大学公共卫生学院贾志荣和陈晓光等筛选建立了白纹伊蚊Aedes albopictus抗溴氰菊酯的实验室品系,并利用RT-PCR和RTq PCR检测了感染登革病毒后0,4,7和10 d白纹伊蚊溴氰     

广东省三株蚊媒黄病毒的鉴定和系统进化分析

为了解广东省蚊媒病毒的种类和分子特征,本研究对从蚊子中分离的三株黄病毒提取病毒核酸并进行二代测序,经序列拼接和比对,基因组序列中缺失的gap通过RT-PCR进行扩增填补。用MEGA软件登录GenBank下载黄病毒代表株序列并绘制进化树,同时用ClustalW2软件与新毒株进行氨基酸同源性比对和编码框序列的分析。结果显示利用二代测序技术获得了三株病毒基因组序列的96.35%～98.26%,并用RT-PCR成功补齐所有gap,序列比对显示其中一株与黄斑库蚊病毒核苷酸和氨基酸同源性98.51%,两株病毒与广平病毒的核苷酸同源性分别为97.30%和89.78%。三株病毒都属于黄病毒家族中的未分类黄病毒或昆虫特异性黄病毒,编码区序列中C蛋白的同源性最低,NS5的同源性最高。本研究发现的三株蚊媒黄病毒中,库蚊黄斑病毒在国内为首次鉴定;两株广平病毒核苷酸同源性存在较大差异,可能存在不同基因亚型。     

福建省2012-2020年麻疹野毒株分子流行病学分析

为了解2012-2020年福建省麻疹野毒株病毒核蛋白N基因及H基因的变化,探讨其流行规律,本研究收集2012年-2020年福建省各地市级麻疹风疹网络实验室检测麻疹病毒核酸阳性的麻疹疑似病例咽拭子标本开展病毒分离,应用RT-PCR方法扩增MV的N基因羧基末端450个核苷酸片段并进行序列测定,通过与WHO推荐24个麻疹病毒基因型参考株、中国S(Shanghai,上海)191疫苗株、H1a中国代表株（China93-2）进行对比分析,从2012-2020年共收到1217例麻疹核酸检测阳性的疑似麻疹病例的病原学标本中,共分离出83株麻疹病毒野毒株,其中76株为H1a亚型,5株B3基因型,2株D8基因型。H1a亚型可分为2个独立谱系Lineage1～2,MV H1a基因型毒株间核苷酸及氨基酸同源性为99.82%～99.98%和99.91%～100%。2018年及2019年福建省首次分离到B3基因型麻疹病毒及D8基因型麻疹病毒为输入性基因型,B3基因型毒株高度同源,D8基因型毒株同源性100%。H1a基因型为福建省本土野毒株优势基因亚型,不同地区不同年代存在同一野毒株持续循环,同一地区同一年份也具...     

登革病毒受体的研究进展

登革病毒(Dengue virus,DENV)是登革热(DF)、登革出血热和登革休克综合征(DHF/DSS)的病原体.根据包膜蛋白的抗原性的不同,DENV可分为4个血清型,即DENV1～4.由于血清型比较复杂,目前关于病毒受体仍未得出明确一致的结论.但近几年取得了一些引人注目的进展,比如研究发现甘露糖受体(MR)、CLEC5A等作为DENV的受体,可能在病毒进入宿主细胞过程中发挥重要作用.为此,就近几年关于DENV受体以及病毒进入细胞的机制作一综述.     

Phylogenetic Analysis of the Dengue Virus Strains Causing the 2019 Dengue Fever Outbreak in Hainan,China

Dengue virus is an arthropod-borne pathogen that is transmitted to humans primarily by Aedes spp.mosquitos,causing the acute infectious disease,dengue fever (DF).Until 2019,no dengue outbreak had been reported in Hainan Province for over20 years.However,in early September of 2019,an increasing number of infected cases appeared and the DF outbreak lasted for over one month in Haikou City,Hainan Province.In our study,we collected 97 plasma samples from DF patients at three hospitals,as well as 1585 mosquito larvae samples from puddles in different areas of Haikou.There were 49(50.5%) plasma samples found to be strongly positive and 9 (9.3%) plasma samples were weakly positive against the NS1 antigen.We discovered DENV both in the patient's plasma samples and mosquito larvae samples,and isolated the virus from C6/36 cells inoculated with the acute phase serum of patients.Phylogenetic analysis revealed that the new strains were the most closely related to the epidemic strain in the southern regions of China,belonging to lineage IV,genotype I,DENV-1.Compared to the seven closest strains from neighboring countries and provinces,a total of 18 amino acid mutations occurred in the coding sequences (CDS) of the new isolated strain,DENV1 HMU-HKU-2.Our data shows that dengue virus is re-emerged in Hainan,and pose new threats for public health.Thus regular molecular epidemiological surveillance is necessary for control and prevention of DENV transmission.     

Epidemiology and vector efficiency during a dengue fever outbreak in Cixi,Zhejiang Province,China

An emigrant worker returning from Southeast Asia triggered the outbreak of a DF epidemic in Zhejiang province, China, in October, 2004. Eighty‐three cases, mainly young and middle‐aged people between 20 and 50 (78.3%), were reported in the area of Cixi. There were no obvious occupational patterns. The majority of cases were female, with a sex ratio of 1:1.86 (m:f). The dengue virus (DENV) strains from the epidemic area were isolated and identified as DENV‐1, which belongs to Asian strain 1. According to the epidemiological investigation, the incidence of DF had no relationship to temperature, humidity, or precipitation, and the Breteau index of larvae showed a clear relationship only with the House Index and Container Index. Recent dengue problems in the town have been associated with the complex social factors and hygienic conditions for endemic villagers and immigrant workers. Some hygienic measures should be taken by the local government to reduce the risk of mosquito‐borne disease. These measures should aim to eliminate the breeding sites of the vector Aedes albopictus in indoor and outdoor containers filled with rainwater and thus reducing the risk of DF transmission.     

Mosquito bite delivery of dengue virus enhances immunogenicity and pathogenesis in humanized mice

Dengue viruses (DENV) are transmitted to humans by the bite of Aedes aegypti or Aedes albopictus mosquitoes, with millions of infections annually in over 100 countries. The diseases they produce, which occur exclusively in humans, are dengue fever (DF) and dengue hemorrhagic fever (DHF). We previously developed a humanized mouse model of DF in which mice transplanted with human hematopoietic stem cells produced signs of DENV disease after injection with low-passage, wild-type isolates. Using these mice, but now allowing infected A. aegypti to transmit dengue virus during feeding, we observed signs of more severe disease (higher and more sustained viremia, erythema, and thrombocytopenia). Infected mice mounted innate (gamma interferon [IFN-γ] and soluble interleukin 2 receptor alpha [sIL-2Rα]) and adaptive (anti-DENV antibodies) immune responses that failed to clear viremia until day 56, while a mosquito bite alone induced strong immunomodulators (tumor necrosis factor alpha [TNF-α], IL-4, and IL-10) and thrombocytopenia. This is the first animal model that allows an evaluation of human immunity to DENV infection after mosquito inoculation.     

Are Aedes albopictus or other mosquito species from northern Italy competent to sustain new arboviral outbreaks?

The Asian tiger mosquito Aedes albopictus (Skuse) (Diptera: Culicidae), native to Southeast Asia, has extended its geographical distribution to invade new temperate and tropical regions. This species was introduced in 1990 to Italy and has since become the main pest in urban settings. It was incriminated as a principal vector in the first European outbreak of chikungunya virus (CHIKV) in the province of Ravenna (Italy) in 2007. This outbreak was associated with CHIKV E1-226V, efficiently transmitted by Ae. albopictus . The occurrence of this outbreak in a temperate country led us to estimate the potential of Ae. albopictus to transmit CHIKV and dengue virus (DENV), and to determine the susceptibility to CHIKV of other mosquito species collected in northern Italy. Experimental infections showed that Ae. albopictus exhibited high disseminated infection rates for CHIKV (75.0% in Alessandria; 90.3% in San Lazzaro) and low disseminated infection rates for DENV-2 (14.3% in San Lazzaro; 38.5% in Alessandria). Moreover, Ae. albopictus was able to attain a high level of viral replication, with CHIKV detectable in the salivary glands at day 2 after infection. In addition, the other three mosquito species, Anopheles maculipennis Meigen, Aedes vexans vexans (Meigen) and Culex pipiens L., showed variable susceptibilities to infection with CHIKV, of 0%, 7.7% and 0–33%, respectively. This information on vector competence is crucial in assessing the risk for an outbreak of CHIKV or DENV in Italy.     

Aedes aegypti, Aedes albopictus, and dengue in Argentina: current knowledge and future directions

Since the reinfestation of South American countries by Ae. aegypti, dengue fever (DF) and dengue hemorrhagic fever (DHF) have become a major public health concern. The aim of this paper was to review the information related with Aedes vectors and dengue in Argentina since the reintroduction of Ae. aegypti in 1986. The geographic distribution of Ae. albopictus is restricted to the Northeast, and that of Ae. aegypti has expanded towards the South and the West in comparison with the records during the eradication campaign in the 1960s. Since 1998, 4,718 DF cases have been reported concentrated in the provinces of Salta, Formosa, Misiones, Jujuy and Corrientes. Despite the circulation of three dengue virus serotypes (DENV-1, -2 and -3) in the North of the country, DHF has not occurred until the present. The information published over the last two decades regarding mosquito abundance, temporal variations, habitat characteristics, competition, and chemical and biological control, was reviewed. Considering the available information, issues pending in Argentina are discussed. The presence of three DENV, the potential spread of Ae. albopictus, and the predicted climate change suggest that dengue situation will get worse in the region. Research efforts should be increased in the Northern provinces, where DHF is currently an actual risk.     

Using recombinant DNA technology for the development of live-attenuated dengue vaccines

Dramatic increases in dengue (DEN) incidence and disease severity have been reported, in great part due to the geographic expansion of Aedes aegypti and Aedes albopictus mosquitoes. One result is the expanded co-circulation of all dengue 1-4 serotype viruses (DENV) in urban areas worldwide, especially in South and South-East Asia, and South America. DEN disease severity ranges from asymptomatic infections to febrile dengue fevers (DF) to life-threatening dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). There is an urgent need for a safe and effective tetravalent DEN vaccine. Several live attenuated, tetravalent DEN vaccine candidates have been generated by recombinant DNA technology; these candidates are capable of providing immunity to all four DENV serotypes. In this paper we review (a) recombinant live-attenuated DEN vaccine candidates in terms of deletion, antigen chimerization, and the introduction of adaptive mutations; (b) strategies for improving tetravalent vaccine attenuation; and (c) live-attenuated DENV vaccine development.     

Cell membrane enolase of Aedes albopictus C6/36 cells is involved in the entrance mechanism of dengue virus (DENV)

Currently, there are no antiviral drugs that effectively reduce the risks and treat the symptoms associated with dengue virus (DENV). Consequently, efforts remain primarily focused on transmission reduction. One such effort concerns DENV receptors in mosquito vectors Aedes aegypti and Aedes albopictus. Despite a lack of direct evidence demonstrating the binding of DENV to cells in mosquito vectors, one putative DENV binding protein has been α-enolase. To develop a deeper understanding, this study tested whether DENV proteins bind to enolase localized in the cytoplasmic membrane of C6/36 cells using both anti-enolase-specific antibodies, and by colocalization analysis, using confocal microscopy.Additionally, to probe the interaction of enolase with the DENV E protein, we performed a docking analysis using PatchDock and FireDock software packages. Study results demonstrate that the DENV E protein interacts with enolase in the plasma membrane of C6/36 cells of Ae. albopictus. Specific anti-enolase antibodies were found to inhibit DENV infection of these cells. Moreover, enolase was found to be localized to the cytoplasmic membrane, cytoplasm, and nucleus. These combined findings suggest that enolase participates in the entrance mechanism of DENV into vector cells.     

An outbreak of dengue virus at Rio de Janeiro--1986

Dengue virus type 1 has been isolated in Aedes albopictus cell strain, from sera of patients living in the Nova Igua?u county, by Rio de Janeiro. The clinical picture was characterized by fever, headache, retrobulbar pain, backache, pains in the muscles and the joints and prostration. Studies in paired sera confirmed the presence of recent infection by dengue virus type 1. The outbreak reached adjacent areas, including Rio de Janeiro city (May, 1986).     

Current progress in dengue vaccines

Dengue is one of the most important emerging vector-borne viral diseases. There are four serotypes of dengue viruses (DENV), each of which is capable of causing self-limited dengue fever (DF) or even life-threatening dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). The major clinical manifestations of severe DENV disease are vascular leakage, thrombocytopenia, and hemorrhage, yet the detailed mechanisms are not fully resolved. Besides the direct effects of the virus, immunopathological aspects are also involved in the development of dengue symptoms. Although no licensed dengue vaccine is yet available, several vaccine candidates are under development, including live attenuated virus vaccines, live chimeric virus vaccines, inactivated virus vaccines, and live recombinant, DNA and subunit vaccines. The live attenuated virus vaccines and live chimeric virus vaccines are undergoing clinical evaluation. The other vaccine candidates have been evaluated in preclinical animal models or are being prepared for clinical trials. For the safety and efficacy of dengue vaccines, the immunopathogenic complications such as antibody-mediated enhancement and autoimmunity of dengue disease need to be considered.